8-K: Hims & Hers Q2 2025 Revenue Jumps 73% on Growth

Hims & Hers Health, Inc. reported robust second quarter 2025 financial results, with revenue up 73% year-over-year to $544.8 million, driven by a 31% increase in subscribers and strong adoption of personalized treatment plans.

Summary

• Revenue for the second quarter of 2025 increased by 73% year-over-year to $544.8 million, up from $315.6 million in Q2 2024.
• Net income for Q2 2025 was $42.5 million, a significant increase from $13.3 million in Q2 2024.
• Adjusted EBITDA more than doubled to $82.2 million in Q2 2025, compared to $39.3 million in Q2 2024.
• Subscribers grew to over 2.4 million by the end of Q2 2025, representing a 31% year-over-year increase.
• Monthly Online Revenue per Average Subscriber increased by 30% year-over-year to $74.
• The company affirmed its full-year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million.
• Net cash used in operating activities was $(19.1) million for Q2 2025, a decrease from $53.6 million provided in Q2 2024.
• Free Cash Flow was $(69.4) million for Q2 2025, down from $47.6 million in Q2 2024, primarily due to temporary working capital investments and increased capital expenditures in pharmacy infrastructure.
• Gross margin decreased to 76% in Q2 2025 from 81% in Q2 2024, mainly due to increased contributions from weight loss offerings.
• The company announced strategic leadership appointments, including a new COO, CTO, and Chief Product Officer, to enhance personalization infrastructure and international expansion.
• International expansion is a key focus, reinforced by the acquisition of ZAVA Global, with an expectation of at least $50 million in revenue from ZAVA through the remainder of 2025.
• Plans include expanding into new specialties like hormonal health and longevity-focused care, and launching standalone lab testing.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant revenue and Adjusted EBITDA growth, coupled with robust subscriber expansion. Strategic initiatives in personalized care, international expansion, and new leadership appointments indicate a clear path for continued growth and market leadership. While cash flow was negative due to investments, this is framed as temporary and necessary for long-term infrastructure development. The affirmed full-year guidance reinforces confidence in future performance.

Positives

• Revenue grew by a strong 73% year-over-year to $544.8 million in Q2 2025, demonstrating robust top-line expansion.
• Net income significantly increased to $42.5 million in Q2 2025, up 220% from $13.3 million in the prior year period.
• Adjusted EBITDA more than doubled to $82.2 million, indicating improved operational efficiency and profitability.
• Subscriber count reached over 2.4 million, a 31% year-over-year increase, showing strong customer acquisition and retention.
• Monthly Online Revenue per Average Subscriber increased by 30% to $74, reflecting higher customer value and product mix optimization.
• The company affirmed its full-year 2025 revenue and Adjusted EBITDA guidance, signaling confidence in continued growth and profitability.
• Strategic acquisitions like ZAVA Global are expected to drive international revenue, with an anticipated $50 million from ZAVA in the latter half of 2025.
• New leadership appointments (COO, CTO, Chief Product Officer) are expected to strengthen operational, technological, and product development capabilities.
• High customer satisfaction reported, with 81% trusting the platform for safe and effective care and 84% confident in expansion into new areas like hormonal health and longevity.

Negatives

• Gross margin decreased to 76% in Q2 2025 from 81% in Q2 2024, primarily due to increased contributions from weight loss offerings.
• Net cash used in operating activities was $(19.1) million in Q2 2025, a significant decline from $53.6 million provided in Q2 2024.
• Free Cash Flow was negative $(69.4) million in Q2 2025, compared to positive $47.6 million in Q2 2024, attributed to temporary working capital investments and increased capital expenditures.
• Wholesale revenue decreased by 10% year-over-year to $7.953 million in Q2 2025.

Risks

• Forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations.
• The company's ability to comply with extensive, complex, and evolving legal and regulatory requirements, including state and federal healthcare, privacy, and consumer protection laws, poses a risk.
• The FDA's resolution of the semaglutide shortage and the conclusion of its enforcement discretion period for 503B outsourcing facilities have constrained and are expected to continue to constrain the ability to provide access to compounded semaglutide on the platform.
• The success of new product launches, market acceptance, customer retention, and the ability to scale the business and expand internationally are subject to various factors and uncertainties.
• The company's ability to invest and generate a return on such investments, manage customer acquisition costs, and achieve operating efficiencies and leverage are ongoing challenges.

Future Outlook

The company expects continued strong growth into the second half of 2025, affirming its full-year revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million. Strategic investments will focus on strengthening personalization infrastructure in pharmacies, expanding lab testing capabilities, and growing international presence. New offerings in hormone health are planned for the coming months, with standalone lab testing and longevity-focused care expected in 2026. International expansion, particularly in Canada with generic semaglutide in 2026, is seen as a significant long-term growth lever with a potential annual revenue opportunity exceeding $1 billion globally.

Management Comments

• Andrew Dudum, co-founder and CEO, stated, "It's never been more clear that we are delivering exactly what millions of people have been waiting for: access to personalized, high-quality care that meets people where they are. From the momentum of our business to the results our customers are achieving, we are more confident than ever that our model is helping people optimize their health and realize the benefits of precision medicine."
• Andrew Dudum also commented, "We believe we're entering an exciting period of growth where we'll enter new, high-impact specialties that bring millions of people in need of care into the market. We expect this broadening offering will transform our platform from a place where customers come to solve a single issue, to one where customers can proactively manage their overall health."
• Yemi Okupe, CFO, noted, "We're seeing consistent growth across our business as we continue to democratize access to precision care. In the second quarter, revenue grew 73% and Adjusted EBITDA more than doubled relative to the prior year; both were driven by robust growth in Subscribers utilizing personalized treatment plans."
• Yemi Okupe further added, "As we move into the second half of 2025, our focus is on investing in capabilities that will deepen the value customers can access on our platform. This includes plans to strengthen the personalization infrastructure in our pharmacies, to expand lab testing capabilities to further tailor care, and to grow our international presence in key markets."

Industry Context

The announcement highlights the growing trend towards personalized digital healthcare and wellness platforms, particularly in areas like weight loss and chronic condition management. Hims & Hers is leveraging technology, data analytics, and artificial intelligence to offer tailored solutions, aligning with the broader industry shift towards precision medicine and consumer-centric care. The expansion into international markets, including the UK, Germany, France, Ireland, and Canada, reflects the global demand for accessible and individualized healthcare options, positioning the company to capitalize on a large addressable market beyond the U.S. The focus on GLP-1 treatments and other specialized areas also places the company at the forefront of high-demand therapeutic categories.

Management Changes

Stakeholder Impact

• **Shareholders**: Positive impact due to strong revenue and Adjusted EBITDA growth, affirmed guidance, and a share repurchase program aimed at offsetting dilution and capitalizing on market value disconnects.
• **Customers**: Enhanced experience through personalized care, new product offerings (e.g., Hers Biotin + Minoxidil Gummy), expanded specialties (hormonal health, longevity), and improved app-oriented tools, leading to high satisfaction and better health outcomes.
• **Employees**: Potential for growth and new opportunities with strategic leadership appointments and expansion into new capabilities and international markets.
• **Creditors**: The issuance of convertible senior notes indicates increased leverage, but strong financial performance and growth trajectory may support debt servicing.
• **Suppliers/Partners**: Increased volume at pharmacies and expansion plans may lead to increased demand for supplies and services, potentially benefiting partners.

Next Steps

• Host a conference call on August 4, 2025, to review Q2 2025 results.
• Focus on investing in capabilities to deepen customer value, including strengthening personalization infrastructure in pharmacies.
• Expand lab testing capabilities to further tailor care.
• Grow international presence in key markets.
• Launch new offerings in hormone health in the coming months.
• Introduce standalone lab testing and expand into longevity-focused care in 2026.
• Begin offering generic semaglutide in Canada in 2026.
• Continue leveraging specialty-specific marketing efforts to drive growth.
• Maintain disciplined execution to drive marketing and Adjusted EBITDA leverage.

Key Dates

Recommendation

The company's Q2 2025 results demonstrate exceptional growth across key metrics, including a 73% increase in revenue and a doubling of Adjusted EBITDA, driven by robust subscriber expansion and strong adoption of personalized treatment plans. The affirmation of full-year guidance signals management's confidence in continued strong performance. Strategic initiatives, such as the acquisition of ZAVA Global for international expansion and the appointment of new leadership to enhance technology and operations, position the company for sustained long-term growth. While there was a temporary negative free cash flow due to investments, this is a strategic move to build out critical infrastructure for future scale. The overall trajectory indicates a company executing well on its growth strategy in a high-demand market.

Keywords

Hims & Hers, HIMS, telehealth, digital health, personalized medicine, Q2 2025 earnings, financial results, healthcare platform, wellness, GLP-1, weight loss, ZAVA Global, international expansion, subscriber growth, Adjusted EBITDA